Table 2. Results of direct comparisons.
| Outcome | Treatment | No. of | No. of | HR/OR(95%CI) | Heterogeneity | |
|---|---|---|---|---|---|---|
| studies | patients | I2 | P | |||
| PFS | S-TKIs vs F-TKIs | 2 | 771 | HR 0.65(0.54–0.77) | 31% | 0.23 |
| F-TKIs+CT vs F-TKIs | 4 | 614 | HR 0.57(0.47–0.70) | 32% | 0.22 | |
| F-TKIs+Bev vs F-TKIs | 2 | 376 | HR 0.56(0.43–0.74) | 0 | 0.55 | |
| F-TKIs vs CT | 10 | 1595 | HR 0.46(0.29–0.72) | 93% | <0.001 | |
| F-TKIs+CT vs CT | 2 | 129 | HR 0.24(0.16–0.37) | 0 | 0.75 | |
| S-TKIs vs CT | 2 | 709 | HR 0.40(0.20–0.83) | 90% | 0.001 | |
| OS | S-TKIs vs F-TKIs | 2 | 771 | HR 0.81(0.67–0.97) | 0 | 0.52 |
| F-TKIs vs CT | 9 | 1423 | HR 1.01(0.88–1.15) | 0 | 0.87 | |
| S-TKIs vs CT | 2 | 709 | HR 0.91(0.74–1.10) | 0 | 0.78 | |
| F-TKIs+CT vs F-TKIs | 2 | 408 | HR 0.70(0.54–0.92) | 0 | 0.93 | |
| F-TKIs+CT vs CT | 2 | 264 | HR 0.71(0.35–1.46) | 78% | 0.03 | |
| SAEs | S-TKIs vs F-TKIs | 2 | 771 | OR 2.29(1.69–3.12) | 0 | 0.58 |
| F-TKIs+CT vs F-TKIs | 2 | 533 | OR 3.79(2.58–5.56) | 0 | 0.58 | |
| F-TKIs+Bev vs F-TKIs | 2 | 376 | OR 4.05(1.04–15.86) | 85% | 0.009 | |
| F-TKIs vs CT | 6 | 1229 | OR 0.30(0.21–0.43) | 48% | 0.09 | |
| S-TKIs vs CT | 2 | 709 | OR 0.68(0.21–2.22) | 92% | <0.001 | |
Abbreviations: No., number; HR, hazard ratio; CI, confidence interval; OR, odds ratio; PFS, progression-free survival; OS, overall survival; SAEs, serious adverse events; TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy.